Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 15:12:940056.
doi: 10.3389/fonc.2022.940056. eCollection 2022.

Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma

Affiliations
Review

Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma

Veronica Zelli et al. Front Oncol. .

Abstract

Extracellular vesicles (EVs), defined as intercellular messengers that carry their cargos between cells, are involved in several physiological and pathological processes. These small membranous vesicles are released by most cells and contain biological molecules, including nucleic acids, proteins and lipids, which can modulate signaling pathways of nearby or distant recipient cells. Exosomes, one the most characterized classes of EVs, include, among others, microRNAs (miRNAs), small non-coding RNAs able to regulate the expression of several genes at post-transcriptional level. In cancer, exosomal miRNAs have been shown to influence tumor behavior and reshape tumor microenvironment. Furthermore, their possible involvement in drug resistance mechanisms has become evident in recent years. Hepatocellular carcinoma (HCC) is the major type of liver cancer, accounting for 75-85% of all liver tumors. Although the improvement in HCC treatment approaches, low therapeutic efficacy in patients with intermediate-advanced HCC is mainly related to the development of tumor metastases, high risk of recurrence and drug resistance. Exosomes have been shown to be involved in pathogenesis and progression of HCC, as well as in drug resistance, by regulating processes such as cell proliferation, epithelial-mesenchymal transition and immune response. Herein, we summarize the current knowledge about the involvement of exosomal miRNAs in HCC therapy, highlighting their role as modulators of therapeutic response, particularly chemotherapy and immunotherapy, as well as possible therapeutic tools.

Keywords: drug resistance; exosomes; hepatocellular carcinoma; miRNAs; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Exosomes biogenesis. After being generated by endocytosis at the level of endosomal system, exosomes are included as invagination within the multivesicular endosomes (MVEs) lumen and released as an outward budding upon the fusion of MVEs with the cell membrane. MVEs formation can occur mainly by endosomal sorting complex required for transport (ESCRT) pathway-dependent mechanism; ESCRT-independent mechanisms were also described. Exosomes can contain different cargos, such as proteins, lipids, DNA, mRNAs, lnRNAs and miRNAs. Exosomes are uptake by recipient cells thus favouring intercellular communication through their autocrine, paracrine and/or endocrine function.

References

    1. Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology, 2nd. New York:Oxford University Press; (2008).
    1. World Health Organization. I.A.f.R.o.C . Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx.
    1. Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: Current status and future perspectives. Biomedicines (2020) 8(12):576. doi: 10.3390/biomedicines8120576 - DOI - PMC - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (2018) 391(10127):1301–14. doi: 10.1016/S0140-6736(18)30010-2 - DOI - PubMed
    1. Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, et al. . Imaging of HCC-current state of the art. Diagn (Basel) (2015) 5(4):513–45. doi: 10.3390/diagnostics5040513 - DOI - PMC - PubMed

LinkOut - more resources